AbCellera Biologics
ABCL
161 hedge funds and large institutions have $1.22B invested in AbCellera Biologics in 2022 Q2 according to their latest regulatory filings, with 54 funds opening new positions, 53 increasing their positions, 28 reducing their positions, and 21 closing their positions.
157% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 21
89% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 28
87% more call options, than puts
Call options by funds: $35.3M | Put options by funds: $18.9M
24% more funds holding
Funds holding: 130 → 161 (+31)
10% more capital invested
Capital invested by funds: $1.1B → $1.22B (+$112M)
1.55% more ownership
Funds ownership: 39.97% → 41.52% (+1.6%)
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
Top Buyers
| 1 |
BlackRock
New York
|
+$79.4M |
| 2 |
State Street
Boston,
Massachusetts
|
+$24.8M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$19.5M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$14.6M |
| 5 |
Millennium Management
New York
|
+$12.4M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
176
Belvedere Trading
Chicago,
Illinois
| – | -$172K | -19,810 | Closed |
|
|
CCM
177
CTC Capital Management
Chicago,
Illinois
| – | -$156K | -16,000 | Closed |
|
|
SM
178
SG3 Management
Dorado,
Puerto Rico
| – | -$49K | -5,000 | Closed |
|
|
CG
179
Cutler Group
San Francisco,
California
| – | -$18.6K | -2,200 | Closed |
|
|
EW
180
Evoke Wealth
Los Angeles,
California
| – | -$12K | -1,200 | Closed |
|
|
BHWM
181
Beaird Harris Wealth Management
Dallas,
Texas
| – | -$6K | -600 | Closed |
|
|
RF
182
Robbins Farley
Bedford,
New Hampshire
| – | -$5K | -500 | Closed |
|
ABCL Hedge Fund Activity: Q2 2022 in Review
161 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in AbCellera Biologics (ABCL) for Q2 2022, worth a combined $1.22B — up 10% from $1.1B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new ABCL positions and 21 closed out — a net gain of 33 holders — while 53 added to existing stakes and 28 trimmed.
The largest buyer was BlackRock, adding an estimated $79.4M. The largest seller was DCVC Bio, cutting an estimated $61.6M.
- 161 institutional investors held AbCellera Biologics (ABCL) as of Q2 2022, up from 130 in Q1 2022.
- Funds reported $1.22B of AbCellera Biologics stock for Q2 2022, up 10% quarter-over-quarter.
- 54 funds opened new AbCellera Biologics positions in Q2 2022 and 21 closed out, a net change of +33 holders.
- The largest AbCellera Biologics buyer in Q2 2022 was BlackRock, an estimated $79.4M added.
- The largest AbCellera Biologics seller in Q2 2022 was DCVC Bio, an estimated $61.6M sold.
Based on aggregated 13F filings for Q2 2022.